{"changeSha256":"c5114ceb1768b392385c539e900a9c0d4337d49307716ac0a16d3f244edc171b","changedAt":"2026-11-14","changedFields":[{"after":"In clinical trials; not FDA-approved","before":"Investigational","field":"Status"},{"after":"An experimental GIP, GLP-1 and glucagon receptor agonist from Eli Lilly. FDA says it is not an approved drug and cannot be used in compounding.","before":"A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.","field":"Profile summary"},{"after":"Published randomized trials, including a Phase 3 diabetes trial, report weight and blood-sugar changes over up to 48 weeks. FDA states that retatrutide has not been found safe and effective for any condition and has warned companies marketing it to consumers.","before":"ClinicalTrials.gov lists an Eli Lilly study as active, not recruiting, with a registry update posted July 20, 2026.","field":"Evidence note"},{"after":"ctg-nct06297603-v25, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-37366315, journal-pmid-37385280, journal-pmid-42250575, ctg-observation-nct05882045-2026-07-30-d21e38ddcccc, ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa, ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10, ctg-observation-nct06383390-2026-08-24-4bb37a90f79a, ctg-observation-nct06297603-2026-11-13-c86dcf0120ca","before":"ctg-nct06297603-v25","field":"Cited source records"},{"after":"Eli Lilly and Company [sources: ctg-nct06297603-v25]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]","before":"Eli Lilly and Company [sources: ctg-nct06297603-v25]","field":"Named organizations"},{"after":"name: ctg-nct06297603-v25; aliases: ctg-nct06297603-v25; category: ctg-nct06297603-v25; status: ctg-nct06297603-v25, ctg-observation-nct06297603-2026-11-13-c86dcf0120ca, fda-unapproved-glp1-concerns-2026-r2; summary: ctg-nct06297603-v25, journal-pmid-42250575, fda-unapproved-glp1-concerns-2026-r2; evidenceNote: journal-pmid-37366315, journal-pmid-42250575, fda-unapproved-glp1-concerns-2026-r2","before":"name: ctg-nct06297603-v25; aliases: ctg-nct06297603-v25; category: ctg-nct06297603-v25; status: ctg-nct06297603-v25; summary: ctg-nct06297603-v25; evidenceNote: ctg-nct06297603-v25","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/retatrutide/versions/3/","version":3},"id":"profile:retatrutide:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that retatrutide cannot be used in compounding.","peptideSlugs":["retatrutide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/retatrutide/v2.json","sha256":"2b1f99298eb366279f250421a842d1e0ad7168fe98b44efe34037c3a6a20f986"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/retatrutide/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-unapproved-glp1-concerns-2026-r2","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","verifiedAt":"2026-11-14"},{"id":"journal-pmid-42250575","name":"The Lancet","sourceClass":"A","title":"Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026) · PMID 42250575","url":"https://doi.org/10.1016/S0140-6736(26)00967-0","verifiedAt":"2026-11-14"},{"id":"ctg-observation-nct06297603-2026-11-13-c86dcf0120ca","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7","url":"https://clinicaltrials.gov/study/NCT06297603","verifiedAt":"2026-11-14"}],"subject":{"slug":"retatrutide","type":"profile"}}
